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Abstract
Background—The purpose of this study was to report the long-term outcome of patients with 
squamous cell cancer (SCC) of the tonsil managed by surgery followed by postoperative 
radiotherapy (PORT).
Methods—Eighty-eight patients treated between 1985 and 2005 were analyzed. Overall survival 
(OS), disease-specific survival (DSS), and recurrence-free survival (RFS) were determined by the 
Kaplan–Meier method. Factors predictive of outcome were determined by univariate and 
multivariate analysis.
Results—Forty-eight percent of patients had T3 to T4 disease and 75% had a positive neck. Five-
year OS, DSS, and RFS were 66%, 82%, and 80%, respectively. The status of the neck was not 
predictive of outcome (DSS 80% for N0 vs 82% for N+; p = .97). Lymphovascular invasion was 
an independent predictor of OS, DSS, and RFS on multivariate analysis.
Conclusion—Lymphovascular invasion but not pathological stage of the neck is an independent 
predictor of outcome in patients with tonsillar SCC.
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INTRODUCTION
Over the past 20 years, the incidence of squamous cell carcinoma (SCC) of the oropharynx 
has increased.1 This increase has been due to a change in etiology of oropharyngeal cancer 
from a smoking and alcohol-related disease to a disease caused by human papillomavirus 
(HPV).1–5 It is now estimated that up to 70% of oropharyngeal cancers are due to HPV.2,3 
The majority of these patients with oropharyngeal SCC are young patients who are usually 
nonsmokers and nondrinkers.3,5,6
Before the development of organ-preservation protocols involving concurrent 
chemoradiation therapy, surgery followed by radiation therapy (RT) was the mainstay of 
treatment for patients with tonsillar SCC, with 5-year disease-specific survival (DSS) rates 
ranging from 61% to 75%.7–9 Over the past 15 years, improvements in chemoradiation have 
resulted in excellent locoregional control rates and DSS rates that are comparable to 
outcome results reported for traditional surgery.10–13 As a result, surgery for patients with 
advanced-stage tonsillar SCC is now rarely carried out. However, 3 observations have 
resulted in a renewed interest in the surgical management of tonsillar SCC. First, recent 
advances in robotic and transoral laser microsurgery have meant that some tonsil tumors 
previously requiring mandibulotomy and free flap surgery can now be treated surgically in a 
more minimally invasive fashion resulting in less morbidity for the patient.14 Second, the 
short-term high-grade acute toxicity of chemoradiation, and the long-term sequelae with 
fibrosis and swallowing difficulties, have dampened the enthusiasm for concurrent 
chemoradiation. Finally, it is now widely accepted that patients with HPV-related tonsillar 
SCC have a superior outcome compared with patients with HPV-negative disease.13,15–17
There is now considerable interest in deintensifying chemoradiation treatments for patients 
with HPV-positive tonsillar SCC by using lower doses of radiation, smaller radiation fields, 
and using alternate chemotherapy agents. These deintensifying treatments may spare 
patients the acute and long-term toxicities associated with platinum-based chemoradiation 
therapy.18,19 A phase 3 trial (Radiation Therapy Oncology Group [RTOG] 1016) 
randomizing patients to concurrent chemoradiation therapy with cisplatin versus cetuximab 
for the treatment of HPV-positive oropharyngeal cancer has recently been initiated.20 An 
alternative approach to deintensifying treatment could be to select patients for minimally 
invasive transoral surgical techniques in conjunction with adjuvant postoperative 
radiotherapy (PORT). Therefore, the purpose of our study was to analyze our experience in 
the management of tonsillar cancer managed by conventional surgery and PORT and 
determine the impact of lymph node status, margin status, extracapsular spread (ECS), and 
HPV status on outcomes.
PATIENTS AND METHODS
After institutional review board approval, patients with tonsillar SCC were identified from 
an institutional database of oropharyngeal cancer treated at Memorial Sloan–Kettering 
Cancer Center between January 1985 and December 2005. Two hundred thirteen patients 
received primary treatment of which 105 had definitive surgery, 81 chemoradiation, 26 
radiation alone, and 1 chemotherapy alone. Of the 105 patients treated with definitive 
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surgery, 13 patients had open neck biopsy for unknown primary, 2 patients had prior head 
and neck radiation, 1 patient had synchronous primaries, and 1 patient had received non-
standard treatment for tonsillar SCC. These patients were excluded, leaving 88 patients 
available for analysis. All patients were treated with surgery and PORT (1 patient did not 
have radiation). No patients had postoperative chemoradiation, as this was before the 
publications by Bernier et al.21 and Cooper et al.22 Details on patient, tumor, and treatment 
characteristics were recorded by retrospective review of patient charts. Pathological review 
was carried out by a pathologist specialized in head and neck pathology (S.D.). To assess 
HPV status of each tumor, we used p16 immunohistochemistry, which is now recognized as 
a surrogate marker for HPV.23 Paraffin blocks were available on 66 patients. Four-
micrometer tumor sections were deparaffinized, and after heat-induced epitope retrieval, 
immunohistochemistry for p16INK4a was performed with the primary antibody dilution of 
1:7 as per manufacturer’s protocol (CINtec Histology Kit, catalog #9517, Roche mtm 
Laboratories AG, Heidelberg, Germany). Cases with nuclear and cytoplasmic 
immunolabeling in at least 70% of the tumor cells were considered positive for p16. Any 
association between survival outcome and p16 status was determined using the chi-square 
test.
Patient, tumor, and treatment characteristics are summarized in Table 1. Median age for the 
entire cohort was 55 years (range, 35–78 years) and 64 (73%) were men. Seventy-seven 
percent of patients were smokers and 70% alcohol drinkers. The p16 status was available in 
66 patients with 48 p16-positive (73%) and 18 p16-negative (27%). Forty two patients 
(48%) had advanced T3/T4 tumors and 75% had a clinically positive neck. Surgical 
approach was transoral in 38%, whereas the remainder required an open approach. 
Mandibulotomy and composite resection was used in 56% and 44% of open approaches, 
respectively. All but 1 patient underwent neck dissection; with 51% receiving a modified 
comprehensive neck dissection, 33% radical neck dissection, and 16% selective neck 
dissection. Sixty-two percent of patients required reconstruction entailing a free flap (40%) 
or pectoralis major myocutaneous flap (20%).
PORT was delivered by conventional RT methods in 82 patients (93%) and by intensity-
modulated radiation therapy (IMRT) in 5 patients (6%). Details regarding target delineation, 
dose specifications, and guidelines used at our center have been previously described in 
detail for both conventional RT24 and IMRT approaches.25 In brief, the median prescription 
dose delivered to the postoperative bed was 63 gray (Gy). If margins were positive, this dose 
was 66 Gy. The radiation dose to the positive neck was 63 Gy and to the contralateral 
negative neck it was 54 Gy. For IMRT patients, the high-risk clinical target volume included 
the preoperative gross disease and the postoperative tumor bed at the primary site, along 
with any nodal regions with disease involvement. The margin for high-risk clinical target 
volume was generally 0.5 cm.
Pathologic staging consisted mainly of T1/T2 tumors, 33% and 49%, respectively. Final 
pathology reports downstaged 10 cT2 and 20 cT3 tumors, as shown in Table 2. The majority 
of tumors were either moderately or poorly differentiated, 41% and 45%, respectively. Other 
important findings included the presence of close (defined as <5 mm) or positive resection 
margins in 49 patients (56%; 20 close and 29 positive), perineural invasion in 14% patients, 
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necrosis in 15% of patients, and lymphovascular invasion in 15% of patients. Seventy-eight 
percent of patients had a pathological positive neck with the majority containing N2 disease 
(64%). In patients with positive neck disease (68 of 88 patients), ECS was present in 41% of 
patients.
Overall survival (OS), DSS, and recurrence-free survival (RFS), were calculated using the 
Kaplan–Meier method. Patients lost to follow-up were censored from analysis at the last 
date of follow-up. Factors predictive of outcome were analyzed by univariate analysis using 
the log-rank test. Factors with a p value of < .05 on univariate analysis or deemed to be of 
clinical significance were then assessed by multivariate analysis using a Cox proportional 
hazards model. Statistical analysis was carried out using commercially available software 
(IBM SPSS for Windows, version 19.0; SPSS, Chicago, IL).
Because of the retrospective nature of the study, assessment of functional outcome of 
speech, airway, diet, and swallowing could not be accurately determined from chart review. 
We therefore used percutaneous endoscopic gastrostomy (PEG) tube dependency as a 
surrogate marker for swallowing dysfunction and tracheostomy dependency as a surrogate 
marker for airway dysfunction.
RESULTS
The median follow-up time was 74 months (range, 1–241 months). OS, DSS, and RFS at 5 
years were 66%, 82%, and 80%, respectively (Figure 1). Seventeen patients had recurrence 
of which 7 were local alone, 2 locoregional, and 8 distant. There were no cases of isolated 
neck recurrence. The 5-year local RFS, regional RFS, locoregional RFS, and distant RFS 
were 89%, 98%, 88%, and 90%, respectively.
Age >60 years, female sex, clinical and pathological T classification, margin status, 
lymphovascular invasion (LVI), and p16 status were predictive of OS on univariate analysis. 
In a multivariate model of the 4 most significant variables (age, pT classification, margin 
status, and LVI), only LVI remained a significant independent predictor (Table 3). Patients 
with LVI were 2.4 times more likely to die compared with those without LVI (5-year OS 
23% vs 73%; p = .04).
LVI and ECS were factors predictive of DSS on univariate analysis, whereas only LVI 
remained significant on multivariate analysis (Table 3). Patients with LVI were 6.9 times 
more likely to die compared to those without LVI (5-year DSS 43% vs 89%; p = .003; 
Figure 2).
Clinical T classification and LVI were factors predictive of RFS on univariate analysis. Once 
again, only LVI held significance on multivariate analysis (Table 3). Patients with LVI were 
5.5 times more likely to have a recurrence compared to those without LVI (5-year RFS 37% 
vs 88%; p = .005).
An important observation was that 64% of patients had N2 disease, yet nodal status was not 
a predictor of DSS or RFS. The 5-year DSS for patients with pathological N0, N1, and N2 
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disease were 80%, 82%, and 83%, respectively. The 5-year RFS for patients with 
pathological N0, N1, and N2 disease were 75%, 81%, and 81%, respectively.
With regard to p16 status, patients who were p16-positive had superior OS and DSS 
compared with patients who were p16-negative (5-year OS 74% vs 47%; p = .04 and 5-year 
DSS 89% vs 66%; p = .08; Figure 3).
For functional outcome, 59 patients (67%) required tracheostomy at the time of initial 
surgery. However, only 1 patient (1.1%) had the tracheostomy still in place at 1 year after 
surgery (Table 4). PEG tube insertion was carried out in 27 patients (31%) either during or 
after primary surgical procedure. Of these, 11 patients (12%) were still PEG-dependent at 1 
year, 8 (9%) were PEG-dependent at 2 years, and 5 (6%) were PEG-dependent at 5 years 
(Table 4).
DISCUSSION
In this study, we report outcome figures for patients with tonsillar SCC managed with 
conventional surgery and PORT. OS, DSS, and RFS in our study were excellent at 66%, 
82%, and 80%, respectively. The 5-year local, regional, and locoregional controls rates were 
also excellent at 89%, 98%, and 88%, respectively. Table 5 is a summary of studies 
published in the literature evaluating tonsillar SCC managed by primary surgery, radiation, 
or both.7–10,12,16,17,26–34 Some series have reported superior results, but these were 
primarily on patients with T1 and T2 primaries in which transoral tonsillectomies were 
carried out.22,23 In comparison to these studies, 48% of our patients had T3/T4 tonsil 
tumors. More recently, a multicenter prospective study of 204 patients with oropharyngeal 
cancer treated with transoral laser microsurgery, reported a 3-year OS, DSS, and disease-free 
survival (DFS) of 86%, 88%, and 82%, respectively.16 In a recent prospective study, 
Haughey et al17 reported his personal experience of 171 patients with p16-positive 
oropharyngeal SCC treated with transoral laser microsurgery with 5-year OS, DSS, and DFS 
of 91%, 94%, 88%, respectively. These excellent survival outcomes coupled with the results 
reported in our study make a strong argument for primary surgical therapy for selected 
patients whose primary tumors are amenable to surgical resection by transoral endoscopic or 
robotic techniques. Our outcome results also compare favorably with nonsurgical series, in 
which survival figures for primary radiation range from 30% to 86%.7–9,29 Recent articles 
from Memorial Sloan–Kettering Cancer Center10 and MD Anderson Cancer Center35 report 
their outcomes in treating oropharyngeal cancer with IMRT. Setton et al10 reported on 442 
patients with tonsillar (50%) and base of tongue (46%) cancer undergoing IMRT and 
concurrent chemotherapy (88%), achieving 3-year OS of 84.9%. Garden et al35 reported on 
the outcomes of 776 patients with oropharyngeal cancer treated with IMRT at MD 
Anderson. In their cohort, 48% were tonsillar SCC and 54% received chemotherapy in either 
an induction or concurrent fashion. They too observed excellent outcomes with 5-year OS of 
84%.
Our multivariate analysis demonstrated only LVI to be an independent predictor of survival. 
This would be in keeping with our observation that in over 50% of patients with recurrence, 
the site of recurrence was distant metastases rather than locoregional. The importance of LVI 
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in other tumor types (eg, breast, gastric, cervical, prostate, and bladder tumors) as a 
prognostic factor is well documented.36–41 However, the significance of LVI in head and 
neck cancer is less well documented with some articles reporting it to be significant17,42 and 
others not.28 Interestingly, patients who were p16-negative were more likely to have LVI 
compared to p16-positive patients (27.8% vs 14.6%; p = .18). When LVI was stratified by 
p16 status, patients who had LVI had a statistically significant poorer DSS in both p16-
positive (60% vs 94%; p = .022) and p16-negative tumors (30% vs 86%; p = .023). However, 
the outcome was most poor in patients with p16-negative LVI-positive tumors.
In our study, nodal involvement was not a significant predictor of survival. Nodal metastasis 
in head and neck cancer is generally associated with a 50% decrease in survival and 
numerous articles demonstrate its significance as a prognostic indicator in all sites of the 
head and neck.43–45 It is possible that nodal metastases in tonsillar cancer are of less 
biological importance and there is evidence from other studies that support this.16,29,34 The 
reason why nodal status is not significant on outcome in tonsillar cancer is an important 
observation, but the reason for this remains unclear. There are 2 possible explanations. First, 
tonsillar cancers are often “lymphoepithelioma like SCC” similar to nasopharyngeal cancer. 
These types of cancers are highly radiosensitive, and, thus, similar to nasopharynx, the status 
of lymph node metastases does not influence outcome.46–49 The other possibility is that this 
may be an HPV-related phenomenon and that nodal metastases in HPV-related 
oropharyngeal cancers are of less biological significance. In the study by Haughey et al16 in 
which nodal status was also reported not to be of significance for recurrence or survival 
outcome, 74% of patients were positive for HPV and 90% stained positive for p16. In our 
series, of 66 patients analyzed, p16 stained positive in 73% patients. In these patients, there 
was no significant difference in DSS in patients who were pN-positive compared to those 
who were pN0 (DSS: 91% vs 75%; p = .26). However, our analysis also showed that in 
patients with p16-negative tumors, nodal status was also not significant (DSS: 62% vs 75%; 
p = .51). This therefore suggests that positive lymph nodes in patients with tonsillar cancer 
does not confer a worse outcome irrespective of p16 status.
The relevance of ECS also requires some discussion. In our study, 41% of lymph nodes had 
ECS. None of these patients had postoperative chemoradiation as these patients were treated 
in an era before the RTOG and European Organization for Research and Treatment of 
Cancer publications by Bernier et al21 and Cooper et al22 that reported reduced locoregional 
recurrence with adjuvant chemoradiation. All patients, except 1, did receive PORT. 
Importantly, there were no cases of isolated neck recurrence and only 2 cases of neck 
recurrence in conjunction with local recurrence. ECS was also not significant on multivariate 
analysis, an observation recently reported by Haughey et al.16 Again, this may be an HPV-
related phenomenon. To examine this further we assessed the impact of ECS on DSS by 
stratifying for p16 status. For patients who were p16-positive, ECS had no impact on DSS; 
the 10-year DSS for ECS-positive versus ECS-negative was 86% versus 92%, p = .65, 
respectively. In contrast, however, ECS had a significant negative impact in patients who 
were p16-negative; the 10-year DSS for ECS-positive versus ECS-negative was 31% versus 
86%, p = .03, respectively. A similar finding was also observed when we assessed the impact 
of positive/close margins on DSS in patients who were p16-positive. Again, margin status 
was only of significance in patients who were p16-negative. In p16-positive patients, the 10-
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year DSS for margin positive/close versus margin negative was 89% versus 87%, p = .83, 
respectively. In contrast, in patients who were p16-negative, the 10-year DSS for margin 
positive/close versus margin negative was 33% versus 86%, p = .07, respectively. However, 
it must be emphasized that our data are based upon retrospective data of a small series of 
patients in whom p16 status was only available on 66 patients. As such, the results have to 
be interpreted with some caution and require further validation on larger surgical series. It is 
possible that the observed lack of significance of nodal status, ECS, and margin status in 
patients who are p16-positive (HPV-positive) may indicate that this is a biologically less 
aggressive disease than p16-negative tonsillar SCC. The most important predictor of 
outcome in our analysis, LVI, was also less common in patients with p16-positive tumors 
indicating a possible association between LVI and p16 status. Our study, therefore, raises 
questions about whether or not there should be a new staging system for oropharyngeal 
cancer, with stratification based on p16 status. Indeed, the RTOG 0129 study reported by 
Ang et al13 introduced a risk stratification system based on p16 status and smoking status. In 
this system, patients were classified as low risk when p16-positive and smoked <10 pack-
years, high risk if p16-negative and smoked >10 pack-years, and intermediate risk if p16-
positive/smoker >10 pack-years, or p16-negative/smoker <10 pack-years. This system 
showed that low risk patients had OS at 3 years over 85%, high risk 45%, and intermediate 
risk 65%. It is possible that this risk classification system may be introduced in the staging 
system for HPV (p16)-positive tonsillar cancer. The adequacy of the current staging system 
is further questioned by a recent 50-year retrospective analysis of 3891 patients with 
oropharyngeal SCC treated at the MDACC.50 After determining a significant survival 
difference between patients treated before and after 1995, patients treated after 1995 with 
nodal disease had significantly better prognosis compared to those without. More specific to 
tonsillar SCC, an Australian multicenter analysis of 489 patients with tonsillar SCC found 
better outcomes in HPV-positive tumors with higher N classification, suggesting that the 
staging is modified by HPV status.51
Our study does have the limitation that it is retrospective and, therefore, susceptible to all the 
problems associated with retrospective data collection and analysis. Despite this, our data 
does show that primary surgery and PORT offers excellent survival outcomes that are 
comparable to results for RT alone and chemoradiation therapy. This data helps support the 
recent renewed interest in the treatment of tonsillar SCC in selected patients by transoral 
surgery with or without the use of new techniques, such as robotic and laser surgery and can 
be used as benchmark data against which the results of these techniques can be compared.
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FIGURE 1. 
Overall, disease-specific, and recurrence-free survival in patients with squamous cell 
carcinoma (SCC) of the tonsil managed by surgery with postoperative radiotherapy (PORT). 
[Color figure can be viewed in the online issue, which is available at 
wileyonlinelibrary.com.]
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FIGURE 2. 
Disease-specific survival stratified by lymphovascular invasion. [Color figure can be viewed 
in the online issue, which is available at wileyonlinelibrary.com.]
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FIGURE 3. 
Disease-specific survival stratified by p16 status. [Color figure can be viewed in the online 
issue, which is available at wileyonlinelibrary.com.]
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TABLE 1
Clinical, pathologic, and treatment characteristics.
Clinical characteristics Pathologic characteristics Treatment characteristics
Baseline
characteristics
No. of
patients (%)
Baseline
characteristics
No. of
patients (%)
Baseline
characteristics
No. of
patients (%)
Sex pT classification Primary surgery
 Male 64 (73)  pT1 28 (32)  S only 1 (1)
 Female 24 (27)  pT2 38 (43)  S + PORT 87 (99)
Age, y  pT3 5 (6) Neck dissection
 <60 64 (73)  pT4 17 (19)  Yes 87 (99)
 >60 24 (27) pN classification   Selective neck dissection 14 (16)
Smoking status  pN0 20 (23)   Modified neck dissection 44 (51)
 Yes 68 (77)  pN1 12 (14)   Radical neck dissection 29 (33)
 No 14 (16)  pN2a 9 (10)  No 1 (1)
 Unknown 6 (7)  pN2b 46 (53) Approach
Alcohol status  pN2c 1 (1)  Transoral 33 (38)
 Yes 62 (70) p Overall stage  Open 55 (62)
 No 18 (20)  I 4 (5)   Mandibulotomy 31 (56)
 Unknown 8 (10)  II 11 (12)   Composite resection
 (mandibulectomy)
24 (44)
Clinical T classification  III 12 (14) Reconstruction
 cT1 18 (20)  IV 61 (69)  Yes 55 (62)
 cT2 28 (32) Margins   Primary 22 (40)
 cT3 28 (32)  Negative 33 (38)   PMMF 11 (20)
 cT4 14 (16)  Positive/close 49 (56)   Free flap 22 (40)
Clinical N classification  Unknown 6 (7)  No 33 (38)
 cN0 23 (26) LVI
 cN1 23 (26)  Yes 13 (15) PORT
 cN2a 15 (17)  No 75 (85) Conventional 82 (93)
 cN2b 22 (25) Necrosis IMRT 5 (6)
 cN2c 3 (3)  Yes 13 (15) None 1 (1)
 cN3 2 (2)  No 75 (85)
PNI
 Yes 12 (14)
 No 76 (86)
ECS
 Yes 28 (41)
 No 40 (59)
Abbreviations: S, surgery; PORT, postoperative radiotherapy; PMMF, pectoralis major myocutaneous flap; LVI, lymphovascular invasion; IMRT, 
intensity-modulated radiation therapy; PNI, perineural invasion; ECS, extracapsular spread.
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TABLE 2
Correlation between clinical T classification and pathologic T classification.
No. of patients by pathologic
T classification
Clinical T classification pT1 pT2 pT3 pT4
cT1 15 3 – –
cT2 10 17 – 1
cT3 3 17 5 1
cT4 – 1 – 15
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TABLE 4
Tracheostomy and percutaneous endoscopic gastrostomy tube dependence.
Tracheostomy tube dependence PEG dependence
Duration
No. of
patients % Duration
No. of
patients %
≤2 wk 30 50.8 ≤4 mo 7 25.9
2–6 wk 23 39.1 4 mo – 1 y 8 29.6
6 wk – 4 mo 3 5.1 1–2 y 3 11.1
4 mo – 1 y 1 1.7 2–5 y 3 11.1
>1 y 1 1.7 >5 y 5 18.5
Unknown 1 1.7 Unknown 1 3.7
Total 59 100 Total 27 100
Abbreviation: PEG, percutaneous endoscopic gastrostomy.
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